SPOTLIGHT: Nycomed to acquire Bradley Pharma


Nycomed is building up its dermatology operations with its deal to buy Bradley Pharmaceuticals. Executives involved in the merger say that the acquisition--at $20 a share--will position Nycomed to in-license and co-promote dermatology products. Paul McGarty, CEO of Nycomed US added: "This brings together the strengths of both companies with the objective of creating a leading specialty pharmaceutical player in dermatology." Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.